Drug intelligence / Profile preview

BR1400-2

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1400-2 is a small molecule drug candidate developed by Boryung Corp. It is one of several related investigational products (including BR1400-1 and BR1400-3) being evaluated for the treatment of hypertension, specifically essential hypertension. The mechanism of action, molecular target(s), and detailed pharmacology have not been publicly disclosed as of June 2025. The drug has undergone Phase 1 clinical trials to assess its pharmacokinetics, pharmacodynamics, and safety in healthy volunteers[1][2][5].

Other names: BR1400-2BR-1400-2BR 1400-2

Beyond the preview

Go deeper on BR1400-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1400-2.

Explore the full profile